Literature DB >> 11591117

Differential effect of IL-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: loss of IL-13 receptors on Burkitt's lymphoma B cells.

K Gee1, M Kozlowski, M Kryworuchko, F Diaz-Mitoma, A Kumar.   

Abstract

IL-4 and IL-13, cytokines with similar biological effects may influence growth and progression of B-cell tumors through regulation of key cell surface molecules important in intercellular communications. In this study, we demonstrate that IL-4 and IL-13 exhibited differential effects on CD23 and CD44 expression and binding to hyaluronan in BL30/B95-8, a Burkitt's lymphoma (BL), and MK3.31, an Epstein-Barr virus transformed normal human B cell line (B-LCL). Studies conducted to understand the molecular mechanisms underlying this differential effect show that IL-4 induced phosphorylation of JAK1, JAK3, and STAT6 in BL30/B95-8 cells and of JAK3 and STAT6 in MK 3.31 cells. In contrast, IL-13 failed to induce the phosphorylation of JAK kinases or STAT6 proteins in these cell lines. The inability of BL30/B95-8 cells to respond to IL-13 was attributed to the loss of expression of IL-13R subunits alpha1 and alpha2, a finding confirmed for a number of other BL cell lines examined. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591117     DOI: 10.1006/cimm.2001.1829

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.

Authors:  Byung-Hak Kim; Jun-Goo Jee; Chang-Hong Yin; Claudio Sandoval; Somasundaram Jayabose; Daisuke Kitamura; Erika A Bach; Gyeong-Hun Baeg
Journal:  Mol Cancer       Date:  2010-02-11       Impact factor: 27.401

2.  Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.

Authors:  Kristopher A Sarosiek; Hovav Nechushtan; Xiaoqing Lu; Joseph D Rosenblatt; Izidore S Lossos
Journal:  Br J Haematol       Date:  2009-08-19       Impact factor: 6.998

3.  Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.

Authors:  Melanie G Cornejo; Michael G Kharas; Miriam B Werneck; Séverine Le Bras; Sandra A Moore; Brian Ball; Marie Beylot-Barry; Scott J Rodig; Jon C Aster; Benjamin H Lee; Harvey Cantor; Jean-Philippe Merlio; D Gary Gilliland; Thomas Mercher
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

4.  Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics.

Authors:  Holger H H Erb; Fabian Guggenberger; Frédéric R Santer; Zoran Culig
Journal:  J Cell Biochem       Date:  2018-01-19       Impact factor: 4.429

5.  Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.

Authors:  Byung-Hak Kim; Eun Hee Yi; Jun-Goo Jee; Ae Jin Jeong; Claudio Sandoval; In-Chul Park; Gyeong Hun Baeg; Sang-Kyu Ye
Journal:  J Cell Mol Med       Date:  2020-06-17       Impact factor: 5.310

6.  Molecular Insights of Hyaluronic Acid-Hydroxychloroquine Conjugate as a Promising Drug in Targeting SARS-CoV-2 Viral Proteins.

Authors:  R Thirumalaisamy; V Aroulmoji; Muhammad Nasir Iqbal; M Deepa; C Sivasankar; Riaz Khan; T Selvankumar
Journal:  J Mol Struct       Date:  2021-04-13       Impact factor: 3.196

7.  An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth.

Authors:  T Liu; A K Chopra
Journal:  Cancer Gene Ther       Date:  2009-08-28       Impact factor: 5.987

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.